Making genome editing a success story in Africa
Hussein M. Abkallo,Patrick Arbuthnot,Thomas O. Auer,Dave K. Berger,Johan Burger,Ereck Chakauya,Jean-Paul Concordet,Abdoulaye Diabate,Vincenzo Di Donato,Jan-Hendrik Groenewald,Amadou Guindo,Lizette L. Koekemoer,Florence Nazare,Tony Nolan,Fredros Okumu,Emma Orefuwa,Lily Paemka,Lucia Prieto-Godino,Steven Runo,Marie Sadler,Kassahun Tesfaye,Leena Tripathi,Charles Wondji
DOI: https://doi.org/10.1038/s41587-024-02187-2
IF: 46.9
2024-03-20
Nature Biotechnology
Abstract:Similar to other biotechnologies, genome editing faces substantial obstacles in Africa. These include regulatory uncertainty, limited access to laboratories, equipment and reagents for molecular biology work, a shortage of trained professionals, and a low rate of returnees among the diaspora. There is also little investment: most countries devote less than 1% of their gross domestic product (GDP) to research and development. The dependency of African institutions on external funding, unequal collaborations with the Global North and control of intellectual property and licensing by foreign entities further hinder progress. Additionally, there are low levels of integration of biotechnology in school and university curricula, inaccurate risk perceptions and apparent low levels of public support (often due to misinformation), and, as a consequence, inadequate political will. Genome editing, in contrast to more classical genetic modification approaches, promises greater accuracy, precision, efficiency and cost-effectiveness and, in turn, a better return on investment. In resource-constrained environments, reducing barriers to the genetics-based innovation offered by genome editing could enable local innovators to be more successful in sectors that are crucial for Africa's biotechnology-based economic development. In addition, genome editing-based health products — including novel gene therapies — can have a notable effect on public health.
biotechnology & applied microbiology